Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 in Combination With Chemotherapy in Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT07392892Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- May 2026
- Primary completion
- Jul 2031
- Modality
- Bispecific Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised trial of PF-08634404 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Pfizer. Primary endpoints: Objective Response Rate at 4 years, Treatment-Emergent Adverse Events at 4 years and 2 more. Started May 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07392892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392892.